Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Blood

Volumn 97, Issue 6, 2001, Pages 1560-1565

  Olavarria, Eduardo ^a   Kanfer, Edward ^a   Szydlo, Richard ^a   Kaeda, Jaspal ^a   Rezvani, Katayoun ^a   Cwynarski, Kate ^a   Pocock, Christopher ^a   Dazzi, Francesco ^a   Craddock, Charles ^a   Apperley, Jane F ^a   Cross, Nicholas C P ^a   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ADULT; ALLOGRAFT; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

EID: 0035869422     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.6.1560     Document Type: Article

References (34)

1. Minimal residual disease in CML
2. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
3. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders
4. Detection of BCR-ABL in hematological malignancies by RT-PCR
5. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
6. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
7. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia
8. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation
9. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT)
10. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
11. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
12. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
13. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation
14. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
15. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation
16. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-therapy by competitive polymerase chain reaction
17. Molecular heterogeneity in complete cytogenetic responders after interferon-therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission
18. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
19. Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
20. Nonparametric estimation from incomplete observations
21. Estimation of failure probabilities in the presence of competing risks
22. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients
23. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 BCR-ABL and p190 BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increasing mixed myeloid chimerism and p190 BCR-ABL detection precede cytogenetic relapse
24. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
25. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
26. Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
27. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific Taq-Man probes
28. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
29. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia: Chronic Leukemia Working Party
30. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation
31. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand
32. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
33. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
34. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia